classical Hodgkin's lymphoma
Oncology · 2017–2017
2decisions
1medicine
1carried consumer input
125individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pembrolizumab Treatment of relapsed or refractory classical Hodgkin lymphoma in patients who have undergone autologous stem cell transplant or are unsuitable for it,… | Aug 2017 | Recommended with restriction | no section in document |
| pembrolizumab Treatment of relapsed or refractory classical Hodgkin's Lymphoma in patients who have progressed following autologous stem cell transplant (ASCT), or who are… | Jul 2017 | Recommended with restriction | 125 individuals |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.